Identifying individuals at clinical high risk for psychosis using a battery of tasks sensitive to symptom mechanisms.

IF 6.2 1区 医学 Q1 PSYCHIATRY
Trevor F Williams, James M Gold, James A Waltz, Jason Schiffman, Lauren M Ellman, Gregory P Strauss, Elaine F Walker, Scott W Woods, Albert R Powers, Joshua Kenney, Minerva K Pappu, Philip R Corlett, Tanya Tran, Steven M Silverstein, Richard E Zinbarg, Vijay A Mittal
{"title":"Identifying individuals at clinical high risk for psychosis using a battery of tasks sensitive to symptom mechanisms.","authors":"Trevor F Williams, James M Gold, James A Waltz, Jason Schiffman, Lauren M Ellman, Gregory P Strauss, Elaine F Walker, Scott W Woods, Albert R Powers, Joshua Kenney, Minerva K Pappu, Philip R Corlett, Tanya Tran, Steven M Silverstein, Richard E Zinbarg, Vijay A Mittal","doi":"10.1038/s41398-025-03539-5","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical high risk for psychosis (CHR-P) population is important for understanding disease progression and treatment; however, standard approaches to identifying CHR-P individuals are expensive and labor-intensive. Focusing on neurocognitive mechanisms that underlie individual psychosis symptoms (positive, negative, and disorganization) may improve screening and identification. The present study examines whether a behavioral task battery that assays symptom mechanisms can identify CHR-P individuals and predict risk severity. Participants (N = 621) were recruited from clinics and the community as part of the Computerized Assessment of Psychosis Risk (CAPR) consortium study. Structured clinical interviews, a dimensional risk calculator, and behavioral tasks were administered. Clinical interviews identified the following groups: (a) CHR-P (n = 273), (b) non-CHR-P individuals with limited psychosis like experiences (PLEs; n = 120), (c) participants with mental disorders and no PLEs (CLN; n = 82), and (d) healthy controls (HC; n = 146). Multinomial logistic regression indicated that the task battery differentiated groups (p < 0.001), with utility for identifying CHR-P individuals (Sensitivity = 0.87, PPV = 0.51, NPV = 0.77), though with high false positives that varied based on comparison group (Specificity = 0.21-0.43). Tasks also predicted psychosis risk calculator scores (Adjusted R<sup>2</sup> = 0.12), with the two unique predictors being positive symptom task variables associated with updating beliefs regarding environmental volatility. Overall, symptom mechanism tasks differentiated CHR-P individuals from control groups, suggesting their potential as novel screening tools. Using tasks to more efficiently identify CHR-P individuals (e.g., enrich samples), may lower barriers and identify individuals that may otherwise be missed.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"311"},"PeriodicalIF":6.2000,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375010/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03539-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

The clinical high risk for psychosis (CHR-P) population is important for understanding disease progression and treatment; however, standard approaches to identifying CHR-P individuals are expensive and labor-intensive. Focusing on neurocognitive mechanisms that underlie individual psychosis symptoms (positive, negative, and disorganization) may improve screening and identification. The present study examines whether a behavioral task battery that assays symptom mechanisms can identify CHR-P individuals and predict risk severity. Participants (N = 621) were recruited from clinics and the community as part of the Computerized Assessment of Psychosis Risk (CAPR) consortium study. Structured clinical interviews, a dimensional risk calculator, and behavioral tasks were administered. Clinical interviews identified the following groups: (a) CHR-P (n = 273), (b) non-CHR-P individuals with limited psychosis like experiences (PLEs; n = 120), (c) participants with mental disorders and no PLEs (CLN; n = 82), and (d) healthy controls (HC; n = 146). Multinomial logistic regression indicated that the task battery differentiated groups (p < 0.001), with utility for identifying CHR-P individuals (Sensitivity = 0.87, PPV = 0.51, NPV = 0.77), though with high false positives that varied based on comparison group (Specificity = 0.21-0.43). Tasks also predicted psychosis risk calculator scores (Adjusted R2 = 0.12), with the two unique predictors being positive symptom task variables associated with updating beliefs regarding environmental volatility. Overall, symptom mechanism tasks differentiated CHR-P individuals from control groups, suggesting their potential as novel screening tools. Using tasks to more efficiently identify CHR-P individuals (e.g., enrich samples), may lower barriers and identify individuals that may otherwise be missed.

Abstract Image

使用一系列对症状机制敏感的任务来识别临床精神病高风险个体。
临床精神病高危人群(chrp)对了解疾病进展和治疗具有重要意义;然而,识别chrp个体的标准方法既昂贵又费力。关注个体精神病症状(阳性、阴性和紊乱)背后的神经认知机制可能会改善筛查和识别。本研究探讨了行为任务组是否可以通过分析症状机制来识别chrp个体并预测风险严重程度。参与者(N = 621)从诊所和社区招募,作为精神病风险计算机化评估(CAPR)联合研究的一部分。采用结构化临床访谈、维度风险计算器和行为任务。临床访谈确定了以下组:(a) chrp - p (n = 273), (b)有有限精神病样经历的非chrp个体(ple, n = 120), (c)有精神障碍但无ple的参与者(CLN, n = 82),以及(d)健康对照组(HC, n = 146)。多项逻辑回归表明,任务组区分组(p 2 = 0.12),两个独特的预测因子是与更新有关环境波动的信念相关的积极症状任务变量。总体而言,症状机制任务将chrp个体与对照组区分开来,表明它们有可能成为新的筛查工具。使用任务更有效地识别chrp个体(例如,丰富样本),可以降低障碍并识别可能被遗漏的个体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.50
自引率
2.90%
发文量
484
审稿时长
23 weeks
期刊介绍: Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信